Champalimaud Clinical Centre
- Address
- lock Available on a paid plan
Extensive‑Stage Small Cell Lung Cancer
The Champalimaud Clinical Centre is evaluating new combination regimens to improve overall survival for patients with extensive‑stage small cell lung carcinoma. The trials aim to compare novel agents with standard chemotherapy and to assess long‑term benefit.
- Novel agent plus etoposide/platinum versus standard therapy
- Overall survival and progression‑free survival endpoints
- Safety and quality‑of‑life monitoring
With 34 investigators, the department leverages its lung‑cancer expertise to advance treatment options for this aggressive disease.
Triple‑Negative Breast Cancer
Researchers are testing immunotherapy in the neoadjuvant setting for triple‑negative breast cancer, seeking higher rates of pathologic complete response (pCR) and better event‑free survival.
- Pembrolizumab combined with chemotherapy before surgery
- Assessment of pCR at definitive surgery
- Follow‑up for long‑term disease‑free outcomes
The trials contribute to the growing evidence base for immune‑based strategies in early‑stage breast cancer.
Gynecologic Squamous Cell Carcinoma Studies
The unit is conducting immunotherapy trials across several gynecologic squamous cell carcinomas, including cervical, vulvar, and anal cancers, to determine the benefit of checkpoint inhibition in these tumor types.
- Pembrolizumab versus physician’s choice therapy
- Evaluation of overall response rate across tumor sites
- Biomarker analysis for PD‑L1 expression
These studies address an unmet need for effective systemic options in squamous cancers of the lower genital tract.
Biomarker‑Driven Immunotherapy in Advanced Solid Tumors
A series of trials focus on patients with advanced solid tumors that harbor specific biomarkers such as MSI‑high, dMMR, or TMB‑high. The goal is to evaluate the activity of pembrolizumab across these molecular subgroups.
- Objective response rate in MSI‑H/dMMR cohorts
- Response assessment in TMB‑high, non‑MSI‑H tumors
- Central radiologic review using RECIST criteria
By targeting genomic instability, the research aims to broaden the applicability of immunotherapy for patients with limited treatment options.
Rare Thoracic and Head‑Neck Tumor Research
The department investigates targeted therapies for less common malignancies such as mesothelioma, thyroid carcinoma, salivary gland carcinoma, and neuroendocrine tumors of the lung and gastrointestinal tract. Studies assess agents like telisotuzumab vedotin and futibatinib for molecularly defined subsets.
- c‑Met overexpressing non‑squamous NSCLC treated with antibody‑drug conjugate
- FGFR‑targeted therapy in advanced cholangiocarcinoma
- Efficacy of novel agents in neuroendocrine and thyroid cancers
These trials highlight the centre’s commitment to precision oncology for rare and challenging tumor types.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 15 therapeutic areas and 15 of 170 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 170 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 24 by active trials.
- 1Merck Sharp & Dohme LLC3active
lock +23 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC9trials
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Champalimaud Clinical Centre
lock Showing 1 of 89 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE-158) | Merck Sharp & Dohme LLC | Phase II | Not Recruiting | Feb 2016 | — |
IMP list
lock Showing 1 of 170 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 21 | Unknown | 2016-02-02 | 2025-09-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.